Shows / GvHD Hub
GvHD Hub
The GvHD Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in GvHD. Our aim is to enhance knowledge in GvHD, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy for more information.
Episodes
- GvHD Hub
How can ECP be positioned in the current GvHD treatment landscape as a steroid-free intervention?
The GvHD Hub spoke with Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, How can ECP be positioned in the current GvHD treatment landscape as a…
- GvHD Hub
What are the key clinical considerations for the use of ECP in steroid-refractory GvHD?
The GvHD Hub spoke with Daniel Wolff, University Hospital Regensburg, Regensburg, DE. We asked, What are the key clinical considerations for the use of ECP in…
- GvHD Hub
What are the challenges involved in enrolling pediatric patients in cGvHD clinical trials?
The GvHD Hub spoke with Andrew Harris, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the challenges involved in enrolling pediatric…
- GvHD Hub
What are the key barriers to patient participation in cGvHD clinical trials?
The GvHD Hub spoke with Steven Pavletic, Bethesda, US. We asked, What are the key barriers to patient participation in cGvHD clinical trials? During this…
- GvHD Hub
What approaches could improve recruitment and retention in cGvHD clinical trials?
The GvHD Hub spoke with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, What approaches could improve recruitment and retention in cGvHD…
- GvHD Hub
How I treat GvHD in children using ECP: Insights from a case study
During the GvHD Hub Steering Committee Meeting in July 2026, key opinion leaders met to discuss how extracorporeal photophoresis (ECP) is used in clinical…
- GvHD Hub
Symposium | Impact of clinical manifestations on treatment selection in SR-cGvHD
During the 8th International Chronic Graft-versus-Host Disease Symposium, the GvHD Hub held a symposium on May 22, 2026, titled Evolving treatment strategies…
- GvHD Hub
Symposium | Emerging treatment strategies for SR-cGvHD
During the 8th International Chronic Graft-versus-Host Disease Symposium, the GvHD Hub held a symposium on May 22, 2026, titled Evolving treatment strategies…
- GvHD Hub
Symposium | Panel discussion: Shifting the treatment paradigm in cGvHD
During the 8th International Chronic Graft-versus-Host Disease Symposium, the GvHD Hub held a symposium on May 22, 2026, titled Evolving treatment strategies…
- GvHD Hub
Symposium | Current treatment options for SR-cGvHD
During the 8th International Chronic Graft-versus-Host Disease Symposium, the GvHD Hub held a symposium on May 22, 2026, titled “Evolving treatment strategies…
- GvHD Hub
How do you approach later-line sequencing in cGvHD in your clinical practice?
The GvHD Hub spoke with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, How do you approach later-line sequencing in cGvHD in your clinical…
- GvHD Hub
How might emerging therapies and combination approaches reshape sequencing strategies in cGvHD?
The GvHD Hub spoke with Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, How might emerging therapies and combination approaches reshape…
- GvHD Hub
What factors drive your decision to switch from first- to second-line therapy for cGvHD?
The GvHD Hub spoke with Daniel Wolff, University Hospital Regensburg, Regensburg, DE. We asked, What factors drive your decision to switch from first- to…
- GvHD Hub
Symposium | Patient’s perspective: My journey with GvHD
During the 52nd Annual Meeting of the EBMT, the GvHD Hub held a symposium on March 24, 2026, titled “Focusing GvHD care through the eyes of providers and…
- GvHD Hub
Symposium | Physician’s perspective: How I treat GvHD with ECP
During the 52nd Annual Meeting of the EBMT, the GvHD Hub held a symposium on March 24, 2026, titled “Focusing GvHD care through the eyes of providers and…
- GvHD Hub
Symposium | The role of nurses within the multidisciplinary GvHD care team
During the 52nd Annual Meeting of the EBMT, the GvHD Hub held a symposium on March 24, 2026, titled “Focusing GvHD care through the eyes of providers and…
- GvHD Hub
What are the treatment options for chronic GvHD-associated fibrosis?
The GvHD Hub was pleased to speak with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, What are the treatment options for chronic…
- GvHD Hub
MSCs: From clinical trials to clinical practice
During the GvHD Hub Steering Committee Meeting in December 2025, key opinion leaders met to discuss the mechanism of action and clinical data supporting the…
- GvHD Hub
Symposium | Early treatment strategies for SR-GvHD
The GvHD Hub held a virtual symposium on October 21, 2025, titled, Guidance vs practice: How can we improve treatment of SR-GvHD? Here, we share a presentation…
- GvHD Hub
Symposium | Quality of life and symptoms in cGvHD
The GvHD Hub held a virtual symposium on October 21, 2025, titled, Guidance vs practice: How can we improve treatment of SR-GvHD. Here, we share a presentation…
- GvHD Hub
What are the treatment options for ruxolitinib-refractory acute GvHD?
The GvHD Hub was pleased to speak with Mohamad Mohty. We asked, What are the treatment options for ruxolitinib-refractory acute GvHD? In this interview…
- GvHD Hub
Symposium | The importance of real-world data in allogeneic stem cell transplantation: A focus on cGvHD
The GvHD Hub held a virtual symposium on October 21, 2025, titled, Guidance vs practice: How can we improve treatment of SR-GvHD? Here, we share a presentation…
- GvHD Hub
What are the current treatment options for steroid-refractory chronic GvHD?
The GvHD Hub was pleased to speak with Robert Zeiser. We asked, What are the current treatment options for steroid-refractory chronic GvHD (SR-cGvHD)? In this…
- GvHD Hub
What are the major challenges in the treatment of SR-GvHD, and how can clinicians overcome these?
Despite advances in preventing chronic graft-versus-host disease (GvHD), transplant recipients continue to be affected, with steroid-refractoriness associated…
- GvHD Hub
How can measurement of QoL and use of PROs be improved in cGvHD?
During the GvHD Hub Steering Committee Meeting on May 12, 2025, key opinion leaders met to discuss how to improve measurement of quality of life (QoL) and use…
- GvHD Hub
ECP + ruxolitinib to prevent cGvHD in patients with SRaGvHD
During the GvHD Hub Steering Committee Meeting on May 12, 2025, key opinion leaders met to discuss the use of extracorporeal photopheresis + ruxolitinib to…
- GvHD Hub
How does real-world evidence complement RCTs, and why is it important for small patient populations?
Real-world evidence (RWE) and randomized controlled trial (RCT) data each have both advantages and disadvantages, and they can be complementary. In general…
- GvHD Hub
Key insights into MSCs for aGvHD – the current clinical trial landscape
This educational resource is independently supported by Medac. All content was developed by SES in collaboration with an expert steering committee; funders…
- GvHD Hub
Future perspectives of ECP for GvHD treatment
The GvHD Hub was pleased to speak to Andrew Gennery, Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK, and Chair of the UK…
- GvHD Hub
Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of…
- GvHD Hub
Symposium | Early intervention and use of ECP combinations in cGvHD
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of…
- GvHD Hub
Symposium | The long-term burden of cGvHD
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of…
- GvHD Hub
Symposium | A brief overview and history of ECP
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of…
- GvHD Hub
What should supportive care look like for patients with chronic GvHD?
During the GvHD Hub Steering Committee meeting in November 2022, key opinion leaders met to discuss what supportive care should look like for patients with…
- GvHD Hub
How would you treat aGvHD in your clinic (an EU perspective)?
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the GvHD Hub was pleased to speak to Gérard Socié, Hôpital…
- GvHD Hub
What should supportive care look like for patients with GvHD? What role does physical activity play in these patients?
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Zinaida Perić…
- GvHD Hub
How do we stratify risk in patients with GvHD?
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Daniel Weisdorf…
- GvHD Hub
What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?
During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to steering committee member Mohamad Mohty, Hôpital Saint-Antoine, Paris…
- GvHD Hub
How can patient-reported QoL change our view on unmet needs in GvHD?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Nada Hamad, St Vincent's Hospital…
- GvHD Hub
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the GvHD Hub was pleased to speak to Christine Spencer, Parker Institute…